查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1812408

细胞免疫疗法市场按治疗类型、来源、适应症、製造方式、最终用户和地区划分

Cellular Immunotherapy Market, By Therapy Type, By Source, By Indication, By Manufacturing Modality, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3个工作天内

价格
简介目录

细胞免疫疗法市场规模预计在 2025 年达到 76.4 亿美元，预计到 2032 年将达到 204.5 亿美元，2025 年至 2032 年的复合年增长率为 15.1%。

报告范围 报告详细信息
基准年 2024 2025年的市场规模 76.4亿美元
效能数据 2020年至2024年 预测期 2020年至2024年
预测期：2025-2032年复合年增长率： 15.10% 2032年的价值预测 204.5亿美元

全球细胞免疫疗法市场代表了现代医学的革命性模式转移，利用人体免疫系统对抗各种疾病，特别是癌症和自体免疫疾病。

这些创新治疗方法涉及提取、改造和重新註入患者免疫细胞，以增强自然防御机制。细胞免疫疗法包括多种治疗方法，包括 CAR-T 细胞疗法、肿瘤浸润淋巴细胞 (TIL) 疗法、自然杀手 (NK) 细胞疗法和树突状细胞疫苗，每种疗法都提供针对特定疾病途径的独特作用机制。

随着Kymriah和Yescarta等CAR-T疗法获得里程碑式的核准，并在治疗难治性骨髓恶性肿瘤方面显示出显着的疗效，市场正经历着前所未有的增长。自动化细胞处理系统和封闭式生物反应器等先进的製造技术显着提高了这些个人化疗法的扩充性和标准化程度。

包括 CRISPR-Cas9 等基因编辑工具、合成生物学平台以及人工智慧驱动的患者选择演算法在内的生物技术创新的融合，持续拓展细胞免疫疗法的治疗潜力。随着全球医疗保健体系逐渐认识到这些活体药物的变革潜力，对研究基础设施、法规结构和报销政策的大量投资正在加速市场采用，并使其能够更好地服务不同的患者群体。

市场动态

全球细胞免疫疗法市场正经历强劲增长，这主要得益于多种引人注目的因素，其中最主要的是全球癌症发病率的不断上升，尤其是骨髓恶性肿瘤，而细胞免疫疗法已在这些领域展现出卓越的临床疗效。大型製药公司、生物技术公司和学术机构对研发活动的大力投入，为细胞免疫疗法市场带来了显着的效益，这些投入正在推动下一代细胞工程技术的创新，并将治疗应用从肿瘤学扩展到自体免疫疾病、感染疾病和再生医学领域。

监管核准途径、突破性疗法认定以及细胞免疫疗法的孤儿药认定正在加速有前景的治疗方法的上市时间，并鼓励持续的投资和开发。

然而，该市场面临着许多限制因素，包括个人化细胞处理相关的极高製造成本、需要专业设施和训练有素的人员的复杂供应链物流，以及在维持产品品质和一致性的同时扩大生产规模的技术挑战。生产週期长，通常需要数週时间才能生产出特异性患者的治疗方法，这带来了额外的营运挑战，并限制了重症患者的治疗机会。

此外，某些细胞免疫疗法相关的严重不利事件，例如细胞激素释放症候群和神经毒性，需要专门的医疗基础设施和专业知识，这限制了其在资源匮乏的医疗机构中的应用。儘管存在这些挑战，但该市场仍提供了巨大的商业机会，具体表现在：将适应症扩展至固体癌瘤（实体瘤的患者群体远大于目前的血液病适应症）；以及开发可大幅降低成本和生产复杂性的现成同种异体细胞疗法，使治疗在全球市场上更易于获得且扩充性。

本次调查的主要特点

  • 本报告对全球细胞免疫疗法市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
  • 它还强调了各个领域的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
  • 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数概述了全球细胞免疫疗法市场的主要企业。
  • 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴车型、市场扩张和行销策略做出明智的决策。
  • 全球细胞免疫疗法市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 透过用于分析全球细胞免疫疗法市场的各种策略矩阵，相关人员将更容易做出决策。

目录

第 1 章：调查目标与先决条件

  • 调查目的
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要

第三章：市场动态、法规与趋势分析

  • 市场动态
  • 驱动程式
  • 抑制因素
  • 机会
  • 影响分析
  • 主要进展
  • 监管情景
  • 产品发布/核准
  • PEST分析
  • 波特分析
  • 併购场景
  • 产业趋势

4. 2020-2032 年全球细胞免疫疗法市场（依疗法类型）

  • CAR T细胞疗法（嵌合体抗原受体T细胞疗法）
  • TCR-T细胞疗法（T细胞受体T细胞疗法）
  • NK细胞疗法（自然杀手细胞疗法）
  • 树突细胞疗法
  • 肿瘤浸润淋巴细胞（TIL）治疗
  • 基于巨噬细胞的细胞疗法
  • 其他（新兴/新型细胞类型）

5. 全球细胞免疫疗法市场（依来源划分），2020-2032 年

  • 自体细胞（患者来源的细胞）
  • 同种异体细胞（供体来源的细胞）

6. 全球细胞免疫疗法市场（依适应症划分），2020-2032 年

  • 癌症
  • 造血系统恶性肿瘤（如白血病、淋巴瘤、骨髓瘤）
  • 感染疾病
  • 病毒感染疾病（如 HIV、HBV、HCV、COVID-19）
  • 自体免疫疾病
  • 多发性硬化症
  • 其他的

7. 2020-2032 年全球细胞免疫疗法市场（依製造方式）

  • 离体细胞扩增
  • 体内工程

8. 2020-2032 年全球细胞免疫治疗市场（依最终用户划分）

  • 医院和诊所
  • 专门内分泌和肥胖中心
  • 门诊手术中心（ASC）
  • 居家医疗服务
  • 其他（学术、研究机构等）

9. 2020-2032 年全球细胞免疫疗法市场（按地区）

  • 北美洲
      • 美国
      • 加拿大
  • 拉丁美洲
      • 巴西
      • 阿根廷
      • 墨西哥
      • 其他拉丁美洲
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
      • 中国
      • 印度
      • 日本
      • 澳洲
      • 韩国
      • ASEAN
      • 其他亚太地区
  • 中东
      • 海湾合作委员会国家
      • 以色列
      • 其他中东地区
  • 非洲
      • 南非
      • 北非
      • 中部非洲

第十章 竞争格局

  • Novartis AG
  • Gilead Sciences Inc（Kite Pharma）
  • Bristol Myers Squibb Company
  • Johnson and Johnson（Janssen Biotech）
  • Cellectis SA
  • Adaptimmune Therapeutics plc
  • Autolus Therapeutics plc
  • Allogene Therapeutics Inc
  • Atara Biotherapeutics Inc
  • Legend Biotech Corporation
  • bluebird bio Inc
  • Fate Therapeutics Inc
  • ImmunityBio Inc
  • Iovance Biotherapeutics Inc
  • Poseida Therapeutics Inc

第 11 章分析师建议

  • 机会
  • 分析师观点
  • Coherent Opportunity Map

第十二章参考文献与调查方法

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI8447

Cellular Immunotherapy Market is estimated to be valued at USD 7.64 Bn in 2025 and is expected to reach USD 20.45 Bn by 2032, growing at a compound annual growth rate (CAGR) of 15.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 7.64 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2020 To 2024
Forecast Period 2025 to 2032 CAGR: 15.10% 2032 Value Projection: USD 20.45 Bn

The global cellular immunotherapy market represents a revolutionary paradigm shift in modern medicine, leveraging the body's own immune system to combat various diseases, particularly cancer and autoimmune disorders.

This innovative therapeutic approach involves extracting, modifying, and reintroducing immune cells back into patients to enhance their natural defense mechanisms. Cellular immunotherapy encompasses diverse treatment modalities including CAR-T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, natural killer (NK) cell therapy, and dendritic cell vaccines, each offering unique mechanisms of action to target specific disease pathways.

The market has witnessed unprecedented growth following breakthrough approvals of CAR-T therapies such as Kymriah and Yescarta, which demonstrated remarkable efficacy in treating refractory hematologic malignancies. Advanced manufacturing technologies, including automated cell processing systems and closed-system bioreactors, have significantly improved the scalability and standardization of these personalized treatments.

The convergence of biotechnology innovations, including gene editing tools like CRISPR-Cas9, synthetic biology platforms, and artificial intelligence-driven patient selection algorithms, continues to expand the therapeutic potential of cellular immunotherapies. As healthcare systems globally recognize the transformative potential of these living medicines, substantial investments in research infrastructure, regulatory frameworks, and reimbursement policies are accelerating market adoption and accessibility across diverse patient populations.

Market Dynamics

The global cellular immunotherapy market experiences robust growth driven by several compelling factors, with the primary driver being the increasing prevalence of cancer worldwide, particularly hematologic malignancies where cellular immunotherapies have demonstrated exceptional clinical outcomes. The market benefits significantly from substantial investments in research and development activities by pharmaceutical giants, biotechnology companies, and academic institutions, fostering innovation in next-generation cell engineering technologies and expanding therapeutic applications beyond oncology into autoimmune diseases, infectious diseases, and regenerative medicine.

Regulatory agencies' establishment of expedited approval pathways, breakthrough therapy designations, and orphan drug status for cellular immunotherapies has accelerated time-to-market for promising treatments, encouraging continued investment and development.

However, the market faces considerable restraints including extremely high manufacturing costs associated with personalized cell processing, complex supply chain logistics requiring specialized facilities and trained personnel, and significant technical challenges in scaling production while maintaining product quality and consistency. Lengthy manufacturing timelines, often requiring weeks to produce patient-specific treatments, pose additional operational challenges and limit treatment accessibility for critically ill patients.

Furthermore, severe adverse events such as cytokine release syndrome and neurotoxicity associated with certain cellular immunotherapies necessitate specialized medical infrastructure and expertise, constraining adoption in healthcare facilities lacking adequate resources. Despite these challenges, the market presents substantial opportunities through expanding applications into solid tumors, which represent a significantly larger patient population than current hematologic indications, and the development of off-the-shelf allogeneic cell therapies that could dramatically reduce costs and manufacturing complexity while improving treatment accessibility and scalability across global markets.

Key Features of the Study

  • This report provides in-depth analysis of the global cellular immunotherapy market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global cellular immunotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Novartis AG, Gilead Sciences Inc (Kite Pharma), Bristol Myers Squibb Company, Johnson and Johnson (Janssen Biotech), Cellectis S.A., Adaptimmune Therapeutics plc, Autolus Therapeutics plc, Allogene Therapeutics Inc, Atara Biotherapeutics Inc, Legend Biotech Corporation, bluebird bio Inc, Fate Therapeutics Inc, ImmunityBio Inc, Iovance Biotherapeutics Inc, and Poseida Therapeutics Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global cellular immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cellular immunotherapy market

Market Segmentation

  • Therapy Type Insights (Revenue, USD Bn, 2020 - 2032)
    • CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell)
    • TCR-T Cell Therapy (T-Cell Receptor T-cell)
    • NK Cell Therapy (Natural Killer cell therapy)
    • Dendritic Cell Therapy
    • Tumor-Infiltrating Lymphocytes (TIL) Therapy
    • Macrophage-Based Cell Therapy
    • Others (emerging/novel cell types)
  • Source Insights (Revenue, USD Bn, 2020 - 2032)
    • Autologous (patient-derived cells)
    • Allogeneic (donor-derived cells)
  • Indication Insights (Revenue, USD Bn, 2020 - 2032)
    • Cancer
    • Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
    • Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)
    • Infectious Diseases
    • Viral Infections (e.g., HIV, HBV, HCV, COVID-19)
    • Bacterial Infections (e.g., tuberculosis)
    • Autoimmune Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Type 1 Diabetes
    • Others
  • Manufacturing Modality Insights (Revenue, USD Bn, 2020 - 2032)
    • Ex Vivo Cell Expansion
    • In Vivo Engineering
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals and Clinics
    • Specialty Endocrinology and Obesity Centers
    • Ambulatory Surgical Centers (ASCs)
    • Home Healthcare Services
    • Others (Academic and Research Institutes, etc.)
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Novartis AG
    • Gilead Sciences Inc (Kite Pharma)
    • Bristol Myers Squibb Company
    • Johnson and Johnson (Janssen Biotech)
    • Cellectis S.A.
    • Adaptimmune Therapeutics plc
    • Autolus Therapeutics plc
    • Allogene Therapeutics Inc
    • Atara Biotherapeutics Inc
    • Legend Biotech Corporation
    • bluebird bio Inc
    • Fate Therapeutics Inc
    • ImmunityBio Inc
    • Iovance Biotherapeutics Inc
    • Poseida Therapeutics Inc

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Cellular Immunotherapy Market, By Therapy Type
    • Global Cellular Immunotherapy Market, By Source
    • Global Cellular Immunotherapy Market, By Indication
    • Global Cellular Immunotherapy Market, By Manufacturing Modality
    • Global Cellular Immunotherapy Market, By End User
    • Global Cellular Immunotherapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Cellular Immunotherapy Market, By Therapy Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • TCR-T Cell Therapy (T-Cell Receptor T-cell)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • NK Cell Therapy (Natural Killer cell therapy)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Dendritic Cell Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Tumor-Infiltrating Lymphocytes (TIL) Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Macrophage-Based Cell Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (emerging/novel cell types)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Cellular Immunotherapy Market, By Source, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Autologous (patient-derived cells)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Allogeneic (donor-derived cells)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Cellular Immunotherapy Market, By Indication, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
    • Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)
  • Infectious Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Viral Infections (e.g., HIV, HBV, HCV, COVID-19)
    • Bacterial Infections (e.g., tuberculosis)
  • Autoimmune Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Type 1 Diabetes
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Cellular Immunotherapy Market, By Manufacturing Modality, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Ex Vivo Cell Expansion
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • In Vivo Engineering
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Cellular Immunotherapy Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals and Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty Endocrinology and Obesity Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Ambulatory Surgical Centers (ASCs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Home Healthcare Services
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (Academic and Research Institutes, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Cellular Immunotherapy Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Therapy Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Source, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Manufacturing Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

10. Competitive landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Gilead Sciences Inc (Kite Pharma)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson and Johnson (Janssen Biotech)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Cellectis S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Adaptimmune Therapeutics plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Autolus Therapeutics plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Allogene Therapeutics Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Atara Biotherapeutics Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Legend Biotech Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • bluebird bio Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fate Therapeutics Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • ImmunityBio Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Iovance Biotherapeutics Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Poseida Therapeutics Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us